-
Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for Ibtrozi (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer
NYSE: $NUVB NEW YORK, Sept. 16, 2026 /PRNewswire/ — Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has approved… Source: Read More
-
New Hope for Glioma Patients: Safusidenib Receives FDA Fast Track Designation
NYSE: $NUVB A Major Milestone in Brain Cancer Research Nuvation Bio has announced a significant development in the fight against brain cancer. The U.S. Food and Drug Administration (FDA) has officially granted Fast Track designation to their investigational drug, safusidenib, for the treatment of patients with IDH1-mutant glioma. What This Means for Patients The FDA’s…